chitin
Chitin (C8H13O5N)n ( KY-tin) is a long-chain polymer of N-acetylglucosamine, an amide derivative of glucose. Chitin is the second most abundant polysaccharide in nature (behind only cellulose); an estimated 1 billion tons of chitin are produced each year in the biosphere. It is a primary component of cell walls in fungi (especially filamentous and mushroom-forming fungi), the exoskeletons of arthropods such as crustaceans and insects, the radulae, cephalopod beaks and gladii of molluscs and in some nematodes and diatoms. It is also synthesised by at least some fish and lissamphibians. Commercially, chitin is extracted from the shells of crabs, shrimps, shellfish and lobsters, which are major by-products of the seafood industry. The structure of chitin is comparable to cellulose, forming crystalline nanofibrils or whiskers. It is functionally comparable to the protein keratin. Chitin has proved useful for several medicinal, industrial and biotechnological purposes. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2006 (NCT00443495)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChitin ↗
Also known as
- chitin
- chitin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01508039 | N/A | Apr 30, 2011 | Aarhus University, CMP Therapeutics Ltd |
| NCT00443495 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2006 | CMP Therapeutics Ltd, Hammersmith Medicines Research |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CMP Therapeutics Ltd | For profit | 2 | 1 | 2 | 2006 |
| Aarhus University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Hammersmith Medicines Research | For profit | 1 | 0 | 1 | 2006 |